Drug news
CHMP rejects Glybera for Lipoprotein Lipase Deficiency
The Committee for Medicinal Products for Human Use (CHMP) has refused, a second time, to approve the gene therapy product Glybera (alipogene tiparvovec)from Amsterdam Molecular Therapeutics' for patients with lipoprotein lipase deficiency. The CHMP considered that there was insufficient evidence that its benefits outweigh its potential risks.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.